Search Results for "Paragard"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Paragard. Results 1 to 7 of 7 total matches.
A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013 (Issue 1412)
on page 22.
OTHER IUDs — Two other IUDs are currently available
in the US. The ParaGard T380A ...
The FDA recently approved Skyla (Bayer), the first new
intrauterine device (IUD) in the US in 12 years. It
releases levonorgestrel, a synthetic progestin, over a
period of 3 years. A table summarizing contraceptive
methods available in the US appears on page 22.
Liletta - A Third Levonorgestrel-Releasing IUD
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
contraception and a rapid return to fertility after removal.
ParaGard T 380A, a copper-containing IUD, Mirena ...
The FDA has approved Liletta, an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy for up to
3 years. The fourth IUD to be approved in the US, and
the third that releases levonorgestrel, Liletta is
comarketed by Actavis and Medicines360, a nonprofit
women's health pharmaceutical company. The wholesale
cost of Liletta is similar to that of other IUDs (see
Table 1), but the manufacturer offers programs that
significantly reduce the cost for commercially-insured
patients and clinics serving low-income women.
Kyleena - Another Hormonal IUD
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
more levonorgestrel.2 ParaGard
T380A, a copper-containing IUD, is FDA-approved for
up to 10 years ...
The FDA has approved Kyleena (Bayer), an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy. It is the
fourth levonorgestrel-releasing IUD to be approved in
the US. Like Mirena, which has been available since
2000, Kyleena is approved for up to 5 years of use.
New Copper IUD
The Medical Letter on Drugs and Therapeutics • Feb 26, 1988 (Issue 760)
FOR
ONLINE USERS
NEW COPPER IUD
The copper T 380A (ParaGard GynoPharma), a new intrauterine contraceptive ...
The copper T 380A (ParaGard - GynoPharma), a new intrauterine contraceptive device (IUD) soon to be marketed in the USA, will be one of only two IUDs available in this country. Progestasert (Alza), which gradually releases progesterone (Medical Letter, 18:65, 1976), is the other.
A Progestin-Releasing Intrauterine Device For Long-Term Contraception
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
, and the copperreleasing ParaGard T 380A, which is effective for 10 years (Medical Letter 1995; 37:9).
THE DEVICE — Mirena ...
The FDA had approved an intrauterine contraceptive device that releases the synthetic progestin levonorgestrel over a period of five years. The device has been available in Europe for 10 years.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
; requires in-office
insertion procedure
Copper-containing IUD
ParaGard (Cooper Surgical) 0.8% 0.6 ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
(ParaGard) and the levonorgestrel
52-mg IUD (Mirena and Liletta) are effective for emergency
contraception ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction